Drug Profile
Research programme: omega-3-fatty acid therapeutics - Matinas BioPharma
Alternative Names: MAT-8800Latest Information Update: 23 Aug 2023
Price :
$50
*
At a glance
- Originator Matinas BioPharma
- Class Hepatoprotectants; Omega 3 fatty acids
- Mechanism of Action Triglyceride modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Fatty liver
Most Recent Events
- 23 Aug 2023 Discontinued - Preclinical for Fatty liver in USA (PO)
- 28 Jan 2019 No recent reports of development identified for preclinical development in Fatty liver in USA (PO)
- 01 Nov 2014 Matinas BioPharma receives patent allowance for Methods of Administering Compositions Comprising Docosapentaenoic Acid in USA